In an in vitro study, TIGIT blockade depleted FoxP3+ Tregs while increasing proliferation of IFNγ-producing CD4+ T cells from peripheral blood from patients with multiple myeloma (42). This evidence concerns the gene TIGIT and plasma cell myeloma.